24th week of 2013 patent applcation highlights part 38 |
Patent application number | Title | Published |
20130149217 | CELL CAPTURING FILTER HAVING HIGH ASPECT RATIO - A cell capturing filter, in which cells or particles having a predetermined size or greater in a sample may be easily captured, and clogging of a flow passage due to the captured cells or particles may be prevented, and stresses acting on the captured cells or particles may be reduced, having a first surface and a second substrate having a second surface that is bonded to the first surface, wherein the first substrate may include a flow passage formed in the first surface of the first substrate so that a sample flows in the flow passage, and a barrier that protrudes across the flow passage, and the second substrate may include a fine groove formed in an area on the second surface corresponding to the barrier, and a gap may exist between a surface of the barrier and the fine groove. | 2013-06-13 |
20130149218 | INSULATOR UNIT - An insulator unit for a multipurpose flow module, such as a plate reactor, comprising a plurality of thermally insulating layers arranged in a sandwich structure with a plurality of plates, to provide thermal insulation across the sandwich structure. | 2013-06-13 |
20130149219 | SEPARATION OF IRON FROM VALUE METALS IN LEACHING OF LATERITE ORES - The invention provides a process for the leaching of a laterite ore, concentrate, tailings or waste rock for the recovery of value metals, at least one value metal being nickel. The laterite ore or concentrate is subjected to a leaching step with a lixiviant comprising hydrochloric acid to leach nickel from the laterite ore, followed by a liquid/solids separation step. The liquid obtained is subject to solvent extraction with a dialkyl ketone, to obtain a solution rich in iron and a raffinate. Separation of iron from cobalt and nickel is obtained. | 2013-06-13 |
20130149220 | CATALYZED SUBSTRATE AND EXHAUST SYSTEM FOR INTERNAL COMBUSTION ENGINE - An exhaust system, and a catalyzed substrate for use in an exhaust system, is disclosed. The exhaust system comprises a lean NO trap and the catalyzed substrate. The catalyzed substrate has a first zone, having a platinum group metal loaded on a support, and a second zone, having copper or iron loaded on a zeolite. The first zone or second zone additionally comprises a base metal oxide or a base metal loaded on an inorganic oxide. Also provided are methods for treating an exhaust gas from an internal combustion engine using the exhaust system. The exhaust system is capable of storing NH | 2013-06-13 |
20130149221 | CATALYSED SUBSTRATE MONOLITH - A catalysed substrate monolith | 2013-06-13 |
20130149222 | EXHAUST SYSTEM FOR A LEAN-BURN IC ENGINE COMPRISING A PGM COMPONENT AND A SCR CATALYST - An exhaust system | 2013-06-13 |
20130149223 | EXHAUST SYSTEM FOR A LEAN-BURN INTERNAL COMBUSTION ENGINE INCLUDING SCR CATALYST - An exhaust system | 2013-06-13 |
20130149224 | SELECTIVE CAUSTIC SCRUBBING USING A DRIVER GAS - Systems and methods are described for selectively removing an acid gas from a feed stream to reduce co-absorption of CO | 2013-06-13 |
20130149225 | Process and Apparatus for Eliminating NOx and N2O - A process for removing N | 2013-06-13 |
20130149226 | INERT GAS RECOVERY AND RECYCLE FOR SILICON CRYSTAL GROWTH PULLING PROCESS - This invention is directed to a method for recovering, purifying and recycling an inert gas on a continual basis in connection with a silicon crystal pulling process. Silicon oxide impurities generated during the crystal growth process are completely oxidized by in-situ oxidation with a regulated amount of an oxidizing source gas mixture to form silicon dioxide impurities, which can be removed by a particulate removal device. The particulate-free effluent enters a purification unit to remove the remaining impurities. The inert gas emerging from the purification unit can be fed back into the crystal puller apparatus and/or mixed with the oxidizing source gas mixture. As a result, the ability to increase silicon crystal throughput, quality and at the same time reduce the costs associated with recycling the inert gas can be achieved. | 2013-06-13 |
20130149227 | METHOD OF PREPARING OLIVINE CATHOD MATERIAL FOR LITHIUM SECONDARY BATTERY - The present invention relates to a method of preparing olivine cathode materials for lithium secondary battery. More specifically, a method of preparing an olivine-based cathode material for secondary battery comprising the steps of: dissolving an iron supplying material, and a lithium phosphate by adding an acid; forming a chelate polymer by adding a chelate agent and a polymerization agent in the solution of the dissolving step followed by heating; pyrolyzing the chelate polymer under reducing atmosphere; and thermally reducing the chelated polymer degraded during the pyrolysis is provided. | 2013-06-13 |
20130149228 | METHOD, SYSTEM AND APPARATUS FOR CONTROLLING PARTICLE SIZE IN A FLUIDIZED BED REACTOR - A method, system, and apparatus for controlling the average particle size and the particle size distribution during a fluidized bed process in a fluidized bed reactor. More particularly, this disclosure relates to a method, system, and apparatus for controlling the average silicon particle size and the silicon particle size distribution during the production of high purity silicon. | 2013-06-13 |
20130149229 | NITROGEN FIXATION BY TITANIUM DIOXIDE - In various embodiments, the present disclosure provides a method of fixing nitrogen. An amount of titania catalyst is provided and contacted with a feed stream that includes nitrogen. The titania catalyst is heated. The heated titania catalyst fixes nitrogen in the feed stream to form nitrogen products, such as nitrates. The nitrogen products are then removed from the titania catalyst. In some examples, the titania catalyst is treated with a base. In further examples, the catalytic process is carried out in the absence of light for photochemically activating the titania catalyst. | 2013-06-13 |
20130149230 | INTEGRATED PROCESS FOR PRODUCING AMMONIUM NITRATE - A process for producing ammonium nitrate is disclosed and in which: | 2013-06-13 |
20130149231 | PROCESS FOR OBTAINING POTASSIUM CHLORIDE - Aspects of the present invention relate to a process to obtain potassium chloride that includes submitting brine to concentration, separating brine after concentration, resulting in a first solid content and a first liquid content, cooling the first liquid content, separating the first liquid content after cooling, thus resulting in a second solid content and a second liquid content, enriching the second solid content, and separating the second solid content after enrichment, thus resulting in a third solid content and a third liquid content. Aspects of this process are environmentally safe, as the process includes stages using solvents and equipment which does not harm the environment. Moreover, aspects of this process present a significant energy consumption reduction. | 2013-06-13 |
20130149232 | METHOD OF PRODUCING PHARMACOLOGICALLY PURE CRYSTALS - The present invention relates to means and methods for producing crystals or crystalline substances. In particular, crystals or crystalline substances which are useful as pharmaceutical ingredients can be manufactured. | 2013-06-13 |
20130149233 | CATION DEFICIENT MATERIALS FOR ELECTRICAL ENERGY STORAGE - A composition comprising: a metal oxide of a first metal ions and second metal ions; an electrically conductive material; and a binder material. The second metal ions have a higher oxidation state than the first metal ions. The presence of the second metal ion increases the number of metal cation vacancies. A method of: dissolving salts of a first metal ion and a second metal ion in water to form a solution; heating the solution to a temperature of about 80-90° C.; and adding a base to the solution to precipitate nanoparticles of a metal oxide of the first metal ion and the second metal ion. | 2013-06-13 |
20130149234 | Continuous Hydrogen Production Device And Method Thereof - The present invention provides a continuous hydrogen production device and method thereof. The device comprises a reaction chamber, a solid raw material inlet, a liquid raw material inlet, a gas outlet, and a temperature controller. The reaction chamber contains an initiation solution, comprising a saturated aluminum hydroxide solution. The solid raw material inlet is used to add aluminum powders into the reaction chamber and the liquid raw material inlet is used to add water into the reaction chamber. The gas outlet is used to collect the produced hydrogen gas. The temperature controller is used to control the temperature of the reaction chamber within a preset reaction temperature range. | 2013-06-13 |
20130149235 | Synthesis Method For ETS-10 Titanosilicate Molecular Sieve - The present invention relates to a synthesis method for ETS-10 titanosilicate molecular sieves. The method comprises the steps of mixing a titanium oxide hydrosol, a silicon source, a sodium hydroxide, a fluorine-containing mineralizer and a water to give a gel and adjusting the pH thereof to 10.4 to 10.8; and hydrothermal crystallizing the gel at 170 to 250° C. for 10 to 100 hours to obtain the ETS-10 titanosilicate molecular sieves. In the synthesis method for ETS-10 titanosilicate molecular sieves provided by the present invention, a titanium oxide hydrosol is used as the titanium source to synthesize the ETS-10 titanosilicate molecular sieves, and the problem that conventional soluble titanium salt-based titanium sources tend to hydrolyze and the problem of poor dispersibility for the titanium source system of insoluble titanium oxide are therefore prevented. The ETS-10 titanosilicate molecular sieves synthesized has high purity and high crystallinity. | 2013-06-13 |
20130149236 | Antibodies Reactive with B7-H3, Immunologically Active Fragments Thereof and Uses Thereof - The present invention relates to antibodies and their fragments that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies and their immunoreactive fragments that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers. | 2013-06-13 |
20130149237 | DELIVERY SYSTEM FOR DIAGNOSTIC AND THERAPEUTIC AGENTS - The invention provides shuttle agents and methods of using the same to facilitate the translocation of therapeutic or diagnostic molecules into the CNS. | 2013-06-13 |
20130149238 | Anti-VEGF Antibody Compositions and Methods - Disclosed are human antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two primary VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new human antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate compositions and methods using the new VEGF-specific human antibodies are also provided. | 2013-06-13 |
20130149239 | 5-PYRROLIDINYLSULFONYL-ISATIN DERIVATIVES - The present invention relates to novel | 2013-06-13 |
20130149240 | 99mTc-LABELED TRIPHENYLPHOSPHONIUM DERIVATIVE CONTRASTING AGENTS AND MOLECULAR PROBES FOR EARLY DETECTION AND IMAGING OF BREAST TUMORS - 99mTc-labeled triphenylphosphonium contrasting agents that target the mitochondria and are useful for early detection of breast tumors using scintimammographic imaging. 99mTc-Mito10-MAG3 possesses advantageous radiopharmaceutical properties. The uptake in the myocardium is reduced by one to two orders of magnitude compared to 99mTc-MIBI. 99mTc-Mito10-MAG3 exhibits fast blood clearance, with a blood half-life of less than 2 minutes in rats. A diminished myocardial uptake combined with a prompt reduction of cardiovascular blood pool signal to facilitate improved signal-to-background ratios. | 2013-06-13 |
20130149241 | PEPTIDE RADIOTRACER COMPOSITIONS - The present invention relates to imaging agent compositions comprising radiolabelled c-Met binding peptides suitable for positron emission tomography (PET) imaging in vivo. The c-Met binding peptides are labelled with the radioisotope | 2013-06-13 |
20130149242 | Labeled Alginate Conjugates for Molecular Imaging Applications - Described are bifunctional NOTA-based derivatives capable of conjugating with alginate and with metal ions, as well as NOTA-alginate conjugates which can be labeled with stable or radioactive metal ions. Also described are conjugation methods of the bifunctional NOTA-based linker with alginate, and methods of using radiometal-labeled NOTA-alginate conjugates or other radio-labeled alginate conjugates as imaging reagents. | 2013-06-13 |
20130149243 | METHOD FOR PRODUCTION OF F-18 LABELED GLUTAMIC ACID DERIVATIVES - This invention relates to methods, which provide access to F-18 labeled glutamic acid derivatives. | 2013-06-13 |
20130149244 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS - The present invention generally relates to novel synthetic methods, systems, kits, salts, and precursors useful in medical imaging. In some embodiments, the present invention provides compositions comprising an imaging agent precursor, which may be formed using the synthetic methods described herein. An imaging agent may be converted to an imaging agent using the methods described herein. In some cases, the imaging agent is enriched in | 2013-06-13 |
20130149245 | Novel Peptides and Uses Thereof - The invention relates to a peptide of 8-50 amino acids comprising the sequence of KAHKKRAD or KARKKHAD, or a cyclic peptide of 8-50 amino acids comprising the sequence of HKKR or RKKH. Also disclosed are methods of using the peptide for detecting, monitoring, or treating cancer. | 2013-06-13 |
20130149246 | Human Monoclonal Antibodies Against Hendra and Nipah Viruses - The present invention relates to monoclonal antibodies that bind or neutralize Hendra or Nipah virus. The invention provides such antibodies, fragments of such antibodies retaining Hendra or Nipah virus-binding ability, fully human antibodies retaining Hendra or Nipah virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention. | 2013-06-13 |
20130149247 | VIVO TUMOR TARGETING AND SPECTROSCOPIC DETECTION WITH SURFACE-ENHANCED RAMAN NANOPARTICLE TAGS - Nanostructures, methods of preparing nanostructures, methods of detecting targets in subjects, and methods of treating diseases in subjects, are disclosed. An embodiment, among others, of the nanostructure includes a metallic gold surface-enhanced Raman scattering nanoparticle, a Raman reporter and a protection structure. The protection structure may include a thiol-polyethylene glycol to which may be attached a target-specific probe. | 2013-06-13 |
20130149248 | AV 6 PEPTIDE LIGANDS AND THEIR USES - AVβ6 peptide ligands, functional variants thereof and their nucleic acids encoding them are disclosed with their uses in the treatment and imaging of AVβ6 mediated diseases. | 2013-06-13 |
20130149249 | IMAGING TUBERCULOSIS WITH PYRAZINAMIDE CONTRAST AGENTS - The present invention provides novel in vivo imaging agents useful for detecting the presence of mycobacteria using in vivo imaging methods. Also provided by the present invention is a precursor compound useful in the synthesis of the in vivo imaging agents of the invention, and a method to obtain the in vivo imaging agent of the invention using said precursor compound. Methods of in vivo imaging and diagnosis in which the in vivo imaging agent of the invention finds use are also provided. | 2013-06-13 |
20130149250 | HYPERPOLARIZED AGENTS FOR MRI CHARACTERIZATION OF REDOX SYSTEMS IN VIVO - The present invention provides a MRI probe of use in detecting and characterizing redox systems in vivo. Also provided are methods of using the probe in MR imaging experiments for diagnosis of disease in a subject, for drug discovery and for probing the redox states of biological systems in vitro. | 2013-06-13 |
20130149251 | OPTICAL SENSOR CONJUGATES FOR DETECTING REACTIVE OXYGEN AND/OR REACTIVE NITROGEN SPECIES IN VIVO - The present invention provides methods and compositions based on optical sensor conjugates that are useful for detecting reactive oxygen, reactive nitrogen, or both species that are a direct result of inflammation caused by tissue damage. | 2013-06-13 |
20130149252 | SWITCHING FLUORESCENT NANOPARTICLE PROBE AND FLUORESCENT PARTICLE IMAGING METHOD USING SAME - The present invention provides a novel fluorescent nanoparticle imaging probe having a switching function (a function to quench a fluorescent dye during nanoparticle preparation, and emit fluorescence during imaging). A switching fluorescent nanoparticle probe comprising: a molecular assembly composed of an amphiphilic block polymer having a hydrophilic block chain and a hydrophobic block chain; and a fluorescent dye encapsulated in the molecular assembly, wherein (a) the hydrophilic block chain comprises, as an essential hydrophilic structural unit, a unit selected from a sarcosine unit and an alkylene oxide unit, (b) the hydrophobic block chain comprises, as an essential hydrophobic structural unit, a unit selected from the group consisting of an amino acid unit and a hydroxylic acid unit, and (c) the fluorescent dye is a cyanine compound represented by the formula (I): | 2013-06-13 |
20130149253 | ORAL DOSAGE FORM OF PREGABALIN - The invention relates to oral dosage forms of pregabalin, preferably for the modified release, and to processes for producing it. | 2013-06-13 |
20130149254 | CHEWABLE POUCH FOR FLAVORED PRODUCT DELIVERY - Provided is a disintegrable or non-disintegrable oral flavor delivery product. The product includes a disintegrable or non-disintegrable chewable pouch with a plurality of perforations. The pouch encloses a non-tobacco flavor product that can be in a gel, semi-liquid, and/or liquid form. A user chews, sucks, and/or manipulates the pouch to cause the enclosed flavor product to leach out of the perforations into the user's mouth. | 2013-06-13 |
20130149255 | VITAMIN B12 COMPOSITIONS - This disclosure provides compositions of vitamin B | 2013-06-13 |
20130149256 | Personal care and medicinal products incorporating orgnosulfur groups - Personal care products useful for the maintenance of personal appearance and good health and minor treatments that do not require professional health care, as well as products that provide a combination of anti-microbial, anti-oxidant, anti-inflammatory, and anti-aging properties and are suitable for use without a prescription. The products utilize a biomembrane permeable organosulfur compound that can redox cycle between thiol, disulfide, and thiosulfinate forms in response to oxidants and antioxidants inside and outside of cells. Example products include an anti-microbial toothpaste with anti-plaque properties, an anti-inflammatory skin lotion with antioxidant, antimicrobial, and deodorant properties, and an anti-toxin skin lotion with anti-arsenicosis properties. | 2013-06-13 |
20130149257 | ANTIMICROBIAL COMPOSITIONS - The present invention relates to the use as an antimicrobial of tamarind seed polysaccharide (TSP) and to antimicrobial compositions which contain it as active ingredient. Antimicrobial compositions containing TSP are particularly useful for topical administration in the treatment and/or prevention of microbial infections of the skin and mucosa. | 2013-06-13 |
20130149258 | RAPIDLY DISSOLVING COMESTIBLE SOLID - A rapidly dissolving comestible solid is disclosed that includes a fondant formed from a super saturated solution having a bulk sweetener, a hydrocolloid, a texturizing agent, and water. Other ingredients may also be added, and in embodiments in which the solid is provided as a breath freshener, flavoring agents, cooling agents and/or other ingredients useful in conventional breath freshening products may be used. A method for making the comestible solid is also disclosed. | 2013-06-13 |
20130149259 | SACCHARIDE SILOXANE COPOLYMERS AND METHODS FOR THEIR PREPARATION AND USE - A novel saccharide siloxane copolymer is useful in personal care compositions. The saccharide siloxane copolymer may be used as a universal emulsifier to prepare low odor emulsions for personal care applications. | 2013-06-13 |
20130149260 | EMULSIONS CONTAINING SACCHARIDE SILOXANE COPOLYMER EMULSIFIERS AND METHODS FOR THEIR PREPARATION AND USE - An emulsion contains a saccharide siloxane copolymer as an emulsifier. The emulsion is useful in formulating personal care products. | 2013-06-13 |
20130149261 | EMULSIONS CONTAINING SACCHARIDE SILOXANE COPOLYMER EMULSIFIERS AND METHODS FOR THEIR PREPARATION AND USE - A saccharide siloxane copolymer is useful as an emulsifier. Emulsions prepared with the saccharide siloxane copolymer are useful in personal care products. | 2013-06-13 |
20130149262 | COMPOSITIONS USEFUL FOR TOOTH WHITENING - The present invention provides tooth whitening compositions in the form of a liquid crystal or a microemulsion that includes a tooth whitening agent in an amount effective to whiten teeth, a hydrophilic phase including water, a hydrophobic phase including at least one oil, at least one anionic, nonionic, amphoteric or zwitterionic surfactant, and a water soluble co-solvent having a Hildebrand solubility parameter above 12 (cal/cm | 2013-06-13 |
20130149263 | Sunless Tanning Compositions with Adjuvants Comprising Sulfur Comprising Moieties - Sunless tanning compositions with adjuvants comprising sulfur comprising moieties are described. The compositions comprise an adjuvant with a +6 oxidation state sulfur moiety and results in excellent artificial tanning results within a consumer acceptable time. | 2013-06-13 |
20130149264 | Cosmetic Compositions Containing Phenolic Compounds - A method of photoprotecting a keratinous substrate comprising applying a composition onto the keratinous substrate, the composition comprising at least one phenolic compound chosen environmental at least one ortho-diphenol, at least one phenolic compound having a carboxylic acid moiety, and mixtures thereof, —a compound chosen from at least one pelyarn!ne, at least one water solvable metal salt, and mixtures thereof; and a cosmetically acceptable carrier. The present disclosure also relates to photoprotective compositions for application onto hair and skin, the compositions comprising at least one phenolic compound chosen from at least one ortho-diphenol, at least one phenolic compound having a carboxylic acid moiety, and mixtures thereof; a compound chosen from at least one polyamine, at least one water soluble metal salt, and mixtures thereof; and a cosmetically acceptable carrier. | 2013-06-13 |
20130149265 | Sunscreen - A sunscreen composition which has an | 2013-06-13 |
20130149266 | Long lasting fingernail lacquer and method for manufacture - The invention provides long lasting and quick drying nail polish compositions for application to natural or artificial nails. The nail polish composition comprises a lacquer component and an optional pigment component. The lacquer component can harden in ambient atmosphere without the use of ultraviolet radiation. The lacquer component includes acrylic polymers dissolved in organic solvents. | 2013-06-13 |
20130149267 | CYCLOSPORINE COMPOSITIONS FOR ENHANCING NAIL GROWTH - The present invention is directed to cyclosporine compositions and methods for stimulating the growth of nails and cuticles in a mammal, including humans. The compositions may be administered topically to the nail bed, nail matrix and cuticle in an amount effective to increase nail growth and thicken, strengthen and smooth the nail. The composition is also effective in strengthening and growing nails, including fingernails and toenails. | 2013-06-13 |
20130149268 | Maesa Japonica Extracts and Methods of Use - Methods of using extracts of | 2013-06-13 |
20130149269 | NOVEL MALODOR COUNTERACTANT - The present invention pertains to a method of counteracting a malodor by introducing a malodor counteracting effective amount of methyl 3-methyl cyclohexane carboxylate. | 2013-06-13 |
20130149270 | ALKALINE HAIR RELAXING COMPOSITION COMPRISING FATTY SUBSTANCE, AND USES THEREOF - A cosmetic composition for relaxing keratin fibres, comprising an alkaline agent, a fatty phase made up of fatty substance(s), the amount of fatty substance being greater than or equal to 52% by weight, relative to the total weight of said composition, and at least one surfactant in an amount of greater than or equal to 5% by weight, relative to the total weight of said composition. The application also relates to a method for relaxing keratin fibres using this composition, and also to the use of this composition for relaxing keratin fibres. | 2013-06-13 |
20130149271 | COMPOSITIONS FOR REPAIRING AND RESTORING KERATIN-CONTAINING FIBERS - Disclosed are compositions that can be used as an adjunct to regular shampooing and conditioning products, wherein the disclosed compositions provide a means for repairing and restoring keratin-containing fibers to their original condition. | 2013-06-13 |
20130149272 | Shampoo Composition Having Improved Care Properties - The invention relates to a cosmetic preparation that contains (a) at least one surfactant selected from anionic, zwitterionic or amphoteric surfactants, (b) a microemulsion and (c) at least one cationic polymer. | 2013-06-13 |
20130149273 | Personal Care Compositions - A personal care composition includes a structured cleansing phase and a benefit phase, the structured cleansing phase having a structuring system that includes an associative polymer and a non-associative polymer. Methods are also provided to increase stability and enhance the deposition of benefit agents. | 2013-06-13 |
20130149274 | COMPOSITIONS AND METHODS FOR SEALING THE SURFACE OF KERATINOUS SUBSTRATES - The present disclosure relates to a composition comprising: (a) at least one polyacid; (b) at least one amino compound chosen from alkyl monoamines, alkoxylated polyamines, alkoxylated monoamines, polyamines and mixtures thereof; and (c) cosmetically acceptable carrier. The present disclosure also relates to a method of sealing the surface of a keratinous substrate using such compositions, including inhibiting loss of hair color. The compositions of the present disclosure may further comprise an auxiliary ingredient. | 2013-06-13 |
20130149275 | AGENTS FOR TEMPORARY SHAPING OF KERATINOUS FIBERS - An agent for treating keratin-containing fibers includes in a cosmetic carrier: (a) a cationic cellulose compound; (b) a copolymer containing a structural unit of Formula (I), a structural unit of Formula (II), and a structural unit of Formula (III) in which R | 2013-06-13 |
20130149276 | CLEANSING COMPOSITION - Cleansing compositions include a mixture of alkyl ether carboxylic acids and/or salts thereof, each having a structure according to formula (1): | 2013-06-13 |
20130149277 | PTEROSTILBENE AND PVP GRAPE JUICE EXTRACT COMBINATION FOR TREATMENT OF METABOLIC, VASCULAR, AND NEURODEGENERATIVE DISORDERS - A pharmaceutical composition is provided comprising a therapeutically effective amount of pterostilbene, a therapeutically effective amount of a polyphenolic-PVP extract of grape juice, and a pharmaceutically acceptable carrier. The embodiments of the pharmaceutical compositions can have lipid lowering properties, or alternatively can have properties that can treat oxidative stress, by decreasing inflammation or inflammatory processes contributing to neurodegenerative diseases. A method of lowering lipid levels in an individual is also provided, comprising administering to the individual in need of such treatment a pharmaceutical composition including a therapeutically effective amount of pterostilbene, a therapeutically effective amount of a polyphenolic-PVP extract of grape juice, and a pharmaceutically acceptable carrier, wherein lipid levels are decreased. | 2013-06-13 |
20130149278 | Insect Control Composition - A composition that attracts insects and which is sufficiently ingested by the insects as to kill the insects, the composition having a boron-containing compound; a saccharide, and a solvent. The composition optionally includes a preservative, at least one organic acid, or an alkali or an alkaline earth sale thereof, and optionally at least one hygroscopic agent. | 2013-06-13 |
20130149279 | HOMOGENEOUS PREPARATIONS OF IL-31 - Homogeneous preparations of human and murine IL-31 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. | 2013-06-13 |
20130149280 | PREPARATIVE REGIMEN FOR ENGRAFTMENT, GROWTH AND DIFFERENTIATION OF NON-HEMATOPOEITIC CELLS IN VIVO AFTER TRANSPLANTATION - The invention relates to methods of obtaining an expanded population of mammalian ex vivo cells and/or for treating a mammalian subject by (a) administering to a subject an effective amount of an agent that confers a growth disadvantage to at least a subset of endogenous cells at the site of engraftment; (b) administering to the subject an effective amount of a mitogenic stimulus for the ex vivo cells; and (c) administering the ex vivo cells to the subject, wherein the ex vivo cells engraft at the site and proliferate to a greater extent than the subset of endogenous cells, to repopulate at least a portion of the engraftment site with the ex vivo cells. The repopulated cells can be harvested for further use or be left at the engraftment site of a subject to be treated. The invention also provides methods of treating brain injury in a subject by engrafting ex vivo cells at the site of injury. | 2013-06-13 |
20130149281 | ORGANIC COMPOUNDS AND THEIR USES - The present application describes a method of treating an HCV-associated disorder by administering to a subject in need thereof a pharmaceutically effective amount of a compound of formula I in combination with an additional HCV-modulating compound. | 2013-06-13 |
20130149282 | FOOD-BASED UTENSILS AND STORAGE CONTAINERS AND METHODS OF MAKING THE SAME - The disclosure relates to edible and biodegradable eating utensils and edible and biodegradable containers. In one aspect a method of making and preserving an edible and biodegradable utensil or container is disclosed. | 2013-06-13 |
20130149283 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS - A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided. | 2013-06-13 |
20130149284 | METHODS OF PRODUCING HUMAN RPE CELLS AND PHARMACEUTICAL PREPARATIONS OF HUMAN RPE CELLS - The present invention provides improved methods for producing retinal pigmented epithelial (RPE) cells from human embryonic stem cells, human induced pluripotent stem (iPS), human adult stem cells, human hematopoietic stem cells, human fetal stem cells, human mesenchymal stem cells, human postpartum stem cells, human multipotent stem cells, or human embryonic germ cells. The RPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The RPE cells described herein are useful for treating retinal degenerative conditions including retinal detachment and macular degeneration. | 2013-06-13 |
20130149285 | ADIPOSE TISSUE-DERIVED STEM CELLS FOR VETERINARY USE - The invention provides for compositions and methods for making and using adipose-derived stem cells for treating non-human mammals for various medical conditions. In particular, the invention provides methods and compositions useful for repair of bone fractures, and for treatment of “dry eye” conditions, acute renal failure, and chronic renal failure in non-human mammals. | 2013-06-13 |
20130149286 | METHODS FOR OBTAINING STEM CELLS - The present invention relates to methods for obtaining stem cells from mammalian cadavers, methods for obtaining or purifying stem cells from a sample likely to contain non-stem cells, methods of regeneration of injured tissues and methods of treatment. | 2013-06-13 |
20130149287 | Corticogenesis of Human Pluripotent Cells - This invention relates to in vitro methods for the induction of corticogenesis in human pluripotent cells, such as iPS cells, by culturing the cells under conditions which stimulate retinoid signalling and inhibit TGFβ superfamily signalling. This may be useful in production of cortical neurons, in particular patient-specific cortical neurons; the modelling of juvenile and adult-onset neurological diseases; and the development of therapeutics. | 2013-06-13 |
20130149288 | METHODS OF GENERATING OLIGODENDROCYTES AND CELL POPULATIONS COMPRISING SAME - A method of generating a population of cells useful for treating a brain disorder in a subject is disclosed. The method comprises contacting mesenchymal stem cells (MSCs) with at least one exogenous miRNA having a nucleic acid sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 15-19 and 27-35, thereby generating the population of cells and/or generating neurotrophic factors that may provide important signals to damaged tissues or locally residing stem cells. MSCs differentiated by miRs may also secrete miRs and deliver them to adjacent cells and therefore provide important signals to neighboring endogenous normal or malignant cells. | 2013-06-13 |
20130149289 | T CELL RECEPTOR MUTANTS - A T cell receptor (TCR) having the property of binding to EVDPIGHLY HLA-A1 complex and comprising a specified wild type TCR which has specific mutations in the TCR alpha variable domain and/or the TCR beta variable domain to increase affinity. Such TCRs are useful for adoptive therapy. | 2013-06-13 |
20130149290 | Engineered Dendritic Cells and Uses for the Treatment of Cancer - This invention provides the field of therapeutics. Most specifically present invention provides methods of generating in vitro engineered dendritic cells conditionally expressing interleukin-12 (IL-12) under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals including human. | 2013-06-13 |
20130149291 | PRODUCTION AND USE OF BACTERIAL HISTAMINE - A method is provided of selecting specific probiotic lactic acid bacteria producing histamine and the use of such strains for beneficial effects for mammals. The method includes selecting a lactic acid bacterial strain for use in the local production of histamine in a mammal, and further comprises screening bacteria for the presence of an. active histidine operon and selecting a strain which has an active histidine operon and is capable of producing histamine. Preferably said strain is selected for its ability to produce histamine at a level of greater than 250 pg/ml. The present invention further provides products comprising the strains obtainable by the selection methods of the invention for use in the local production, of histamine in a mammal, in particular for use in the treatment or prophylaxis of inflammatory conditions. | 2013-06-13 |
20130149292 | THROMBIN-FREE BIOLOGICAL ADHESIVE AND USE THEREOF AS A MEDICAMENT - The invention relates to a thrombin-free, fibrinogen-based biological adhesive for therapeutic use, which comprises factor Vila and a source of calcium ions. The invention also relates to the use of the biological adhesive as a medicament, in particular as a dressing for biological tissues, wounds or biomaterials. | 2013-06-13 |
20130149293 | STABLE COMPOSITIONS OF FACTOR IX - The invention allows substantial improvements in stability of coagulation Factor IX in aqueous compositions. An aqueous composition sealed in a non-glass container comprising Factor IX in a buffer and calcium ions is provided, together with methods of stabilizing an aqueous Factor IX composition comprising storing said composition in a non-glass container for at least 7 days. | 2013-06-13 |
20130149294 | OSTEOGENIC DEVICES AND METHODS OF USE THEREOF FOR REPAIR OF ENDOCHONDRAL BONE, OSTEOCHONDRAL AND CHONDRAL DEFECTS - Disclosed herein are improved osteogenic devices and methods of use thereof for repair of bone and cartilage defects. The devices and methods promote accelerated formation of repair tissue with enhanced stability using less osteogenic protein than devices in the art. Defects susceptible to repair with the instant invention include, but are not limited to: critical size defects, non-critical size defects, non-union fractures, fractures, osteochondral defects, subchondral defects, and detects resulting from degenerative diseases such as osteochondritis dessicans. | 2013-06-13 |
20130149295 | FURIN AND BIOLOGICALLY ACTIVE DERIVATIVES THEREOF FOR USE IN THE PREVENTION OR TREATMENT OF AN INFLAMMATORY DISEASE - The present invention relates to the prevention or therapy of inflammatory diseases. More particularly, the invention relates to an isolated polypeptide comprising the subtilisin-like catalytic domain of the furin or a biologically active derivative thereof, for use in the prevention or treatment of an inflammatory disease. | 2013-06-13 |
20130149296 | Salts of Isophosphoramide Mustard and Analogs Thereof As Anti-Tumor Agents - The present disclosure relates to salts and compositions of isophosphoramide mustard and isophosphoramide mustard analogs. In one embodiment the salts can be represented by the formula I: | 2013-06-13 |
20130149297 | ROLE OF FRAGILE X MENTAL RETARDATION GENE AND PROTEIN IN CANCER METASTASIS - The present application relates to the field of cancer. Surprisingly, it was shown that the Fragile X mental retardation gene (Fmr1) products such as the FMRP protein, primarily implicated in mental retardation, are upregulated in metastasizing tumours. It is shown how Fmr1 gene products can be used as a marker for cancer metastasis and how inhibition of these gene products may help prevent or reduce metastasis. | 2013-06-13 |
20130149298 | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin - The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same. | 2013-06-13 |
20130149299 | DOSAGES FOR TREATMENT WITH ANTI-EGFR ANTIBODIES - The present invention concerns dosages for treatment of human cancer patients with an anti-Epidermal Growth Factor Receptor (EGFR) antibody. | 2013-06-13 |
20130149300 | MONOCLONAL ANTIBODIES WITH ALTERED AFFINITIES FOR HUMAN FCyRI, FCyRIIIa, AND C1q PROTEINS - Disclosed herein are GNGN and G1/G2 antibodies that recognize and bind various FcRs and C1 | 2013-06-13 |
20130149301 | ANTI-CD137 ANTIBODY AS AN AGENT IN THE TREATMENT OF INFLAMMATORY CONDITIONS - The present invention relates to the treatment of inflammatory conditions including atherosclerosis and sepsis. In particular, the invention relates to treatment of these conditions using antibodies. | 2013-06-13 |
20130149302 | THERAPEUTIC AGENTS FOR PANCREATIC CANCER - We achieved the present invention on the basis of the finding that an excellent therapeutic effect against pancreatic cancer can be obtained by administering an XL-6 inhibitor and an antimetabolite to pancreatic cancer patients. We also found that metastatic lesions from human pancreatic cancer can be reduced and ascites can be eliminated. | 2013-06-13 |
20130149303 | IMMUNOTHERAPEUTIC METHOD INVOLVING CD123 (IL-3Ra) ANTIBODIES AND IMMUNOSTIMULATING COMPLEX - A method for the treatment of a condition which is characterized by CD 123-expressing cells in a patient comprises administering to the patient (i) an antibody or antibody fragment which binds selectively to IL- | 2013-06-13 |
20130149304 | USE OF MODULATORS OF COMPOUNDS OF TGF-BETA SUPERFAMILY TO REGULATE HEPCIDIN-MEDIATED IRON METABOLISM - The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular, methods of using agonists and antagonists of TGF-β superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders. | 2013-06-13 |
20130149305 | SOLUBLE CD80 AS A THERAPEUTIC TO REVERSE IMMUNE SUPRESSION IN CANCER PATIENTS - The present invention provides for a therapeutic cancer treatment using a soluble CD80 fusion protein that binds to PDLL and inhibits PDLL-PD1 interactions thereby overcoming PDLL-induced immune suppression and restoring T cell activation. | 2013-06-13 |
20130149306 | Antagonists of Sema3E/PlexinD1 interaction as anti-cancer agents - The present invention is related to the treatment of certain cancers using antagonists of the binding between a Plexin and a Sema3E. The invention may be helpful in treating primary cancer cell development and metastasis development wherein Sema3E is expressed, in particular overexpressed by the tumoral cells or the stroma. Breast cancer, in particular with distant metastases is concerned. Prostate cancer, melanoma and glioblastoma are also concerned. The antagonist may be any molecule that specifically binds to PlexinD1 or Sema3E and blocks the Sema3E/PlexinD1 binding. In an embodiment, the antagonist is a polypeptide or an antibody. | 2013-06-13 |
20130149307 | HUMANIZED ANTI-EGFL7 ANTIBODIES AND METHODS USING SAME - The present invention concerns antibodies to EGFL7 and the uses of same. | 2013-06-13 |
20130149308 | ANTIBODIES TO IL-1BETA AND IL-18, FOR TREATMENT OF DISEASE - The present invention relates to compositions and methods for treatment of disease. More particularly, the present invention relates to anti-IL-1β and anti-IL-18 antibodies, including anti-IL-1β and anti-IL-18 bispecific antibodies, and methods of treating disease using such antibodies. | 2013-06-13 |
20130149309 | NOVEL REGULATORY PROTEINS AND INHIBITORS - The invention provides a previously uncharacterized protein (gamma secretase activating protein or gSAP) that activates γ-secretase to produce β-amyloid protein (Aβ). Deposition of Aβ has been associated with Alzheimer's disease and other pathologies. The invention thus additionally provides, e.g., screening methods and novel research tools, inhibitors of this novel protein, and methods of diagnosis, treatment and control of Alzheimer's disease and other neurodegenerative conditions associated with deposition of Aβ. | 2013-06-13 |
20130149310 | COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME - The present invention provides compositions and methods of treating and improving the symptoms of rheumatoid arthritis using an antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). | 2013-06-13 |
20130149311 | GFI1B MODULATION AND USES THEREOF - Methods, uses and kits for increasing the number of hematopoietic stem cells (HSCs) in a biological system, such as for increasing the number of HSCs in the bone marrow and/or blood of a subject, based on the modulation of growth factor independence 1b (Gfi1b), are disclosed. | 2013-06-13 |
20130149312 | COMPOSITIONS AND METHODS FOR TREATING COPD EXACERBATION - This disclosure relates to methods of treating exacerbation of chronic obstructive pulmonary disease (COPD) with antibodies and antagonists to interleukin 1 receptor 1 (IL-1R1) or IL-1α. | 2013-06-13 |
20130149313 | ANTIBODIES TO RECEPTOR OF ADVANCED GLYCATION END PRODUCTS (RAGE) AND USES THEREOF - The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example missfolded proteins like amyloid β and advanced glycation-end-products. | 2013-06-13 |
20130149314 | p19Arf, HMGA2 and MDM2 For Use in the Diagnosis and Treatment of Aberrant Cell Growth - Provided are novel methods and compositions for the diagnosis, prognosis and treatment of leiomyomas, in particular uterine leiomyoma (UL). In addition, methods of identifying anti-tumor agents are described. Furthermore, novel methods and compositions are provided for the treatment of diseases characterized by an aberrant growth of mesenchymal stem cells and their descendants and for the treatment of obesity are disclosed. | 2013-06-13 |
20130149315 | ANTIBODIES AGAINST GLUCAGON RECEPTOR AND THEIR USE - Disclosed are immunological compositions and methods for reducing activity of glucagon signaling using antibodies against glucagon receptor. | 2013-06-13 |
20130149316 | Antibodies That Specifically Bind to Abeta Oligomers and Uses Thereof - The present inventors successfully produced monoclonal antibodies that are specific to only soluble Aβ oligomers, but do not recognize soluble Aβ monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease. | 2013-06-13 |